Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A

Abstract

Background. Hypertension and nephrotoxicity are well-known side-effects of cyclosporine A (CsA). CsA-induced vasoconstriction of the afferent glomerular arteriole probably plays a role in at least the nephrotoxicity. Frequently renal transplant recipients on CsA have to be treated with antihypertensive drugs and for this purpose also β-blockers are used. Tertatolol is a new β-blocker with specific vasodilatory properties, and thus might be particularly useful in CsA-treated transplant recipients. Methods. We studied the systemic and renal haemodynamic effects of atenolol and tertatolol in 12 hypertensive renal transplant recipients on cyclosporine A (CsA). In a cross-over way, all patients were treated with atenolol and tertatolol for 4 weeks each, separated by a wash-out period also of 4 weeks. At the end of each period, the mean arterial pressure (MAP), heart rate, glomerular filtration rate (GFR and renal plasma flow (RPF) were measured. Results. The mean arterial pressure was lower (P < 0.05) during atenolol (124 ± 2 mmHg) and tertatolol (125 ± 2 mmHg) treatment compared with washout (132 ± 4 mmHg). Also the heart rate was lower (P < 0.01) during atenolol and tertatolol (54 ± 3 and 55 ± 2 beats/min respectively) than in the wash-out period (65 ± 3 beats/min). GFR and RPF were not changed by either β-blocker. Conclusion. In CsA treated renal transplant recipients both atenolol and tertatolol effectively reduced blood pressure. In these patients we found no evidence of a specific vasodilatory effect of tertatolol. Both β-blockers had no negative influence on renal function. Hence, these cardioprotective agents are an attractive and safe choice for the treatment of hypertension in such patients.